Researchers at Roswell Park Comprehensive Cancer Center have identified a cause of resistance to doxorubicin in triple-negative breast cancer. The team’s new study in Scientific Reports points to a new strategy for overcoming this resistance to treatment, using drugs known as IMPDH2 inhibitors.
Your privacy is our priority
- Hosted on Secure cloud-based hosting
- SOC II Type 1
- HIPAA compliant
- 2FA authentication
- End-to-end data encryption
- Your health data will not be sold or used without your consent. Ever.
